2lpapi®

Phase 3

LLabo'Life

2lpapi® is one of 5 therapeutic programs targeting Human Papilloma Virus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Human Papilloma VirusRecruiting

Human Papilloma VirusPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Human Papilloma Virus

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 2

1 2

Keytruda

Merck & Co.

Phase 2

1 3

2lpapi®

LLabo'Life

Phase 3

1 4

Human Recombinant Growth Hormone

UUniversity of Maryland, Baltimore

Phase 2

1 5

Gardasil9

Merck & Co.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

ApprovedRecruiting

Human Papilloma Virus

NCT04232917

Clinical

Trials by Indication[1]

Human Papilloma Virus1 trial

Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections.

Recruiting·LLabo'Life·Approved·NCT04232917·284 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 2lpapi®. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 2lpapi®. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Labo'Life company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: LLabo'Life

2lpapi®

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Human Papilloma Virus1 trial

References

Drug Info

Quick Facts

Related News